TY - JOUR A1 - Pilgram, Lisa A1 - Eberwein, Lukas A1 - Wille, Kai A1 - Koehler, Felix C. A1 - Stecher, Melanie A1 - Rieg, Siegbert A1 - Kielstein, Jan T. A1 - Jakob, Carolin E. M. A1 - Rüthrich, Maria A1 - Burst, Volker A1 - Prasser, Fabian A1 - Borgmann, Stefan A1 - Müller, Roman-Ulrich A1 - Lanznaster, Julia A1 - Isberner, Nora A1 - Tometten, Lukas A1 - Dolff, Sebastian T1 - Clinical course and predictive risk factors for fatal outcome of SARS-CoV-2 infection in patients with chronic kidney disease JF - Infection N2 - Purpose The ongoing pandemic caused by the novel severe acute respiratory coronavirus 2 (SARS-CoV-2) has stressed health systems worldwide. Patients with chronic kidney disease (CKD) seem to be more prone to a severe course of coronavirus disease (COVID-19) due to comorbidities and an altered immune system. The study’s aim was to identify factors predicting mortality among SARS-CoV-2-infected patients with CKD. Methods We analyzed 2817 SARS-CoV-2-infected patients enrolled in the Lean European Open Survey on SARS-CoV-2-infected patients and identified 426 patients with pre-existing CKD. Group comparisons were performed via Chi-squared test. Using univariate and multivariable logistic regression, predictive factors for mortality were identified. Results Comparative analyses to patients without CKD revealed a higher mortality (140/426, 32.9% versus 354/2391, 14.8%). Higher age could be confirmed as a demographic predictor for mortality in CKD patients (> 85 years compared to 15–65 years, adjusted odds ratio (aOR) 6.49, 95% CI 1.27–33.20, p = 0.025). We further identified markedly elevated lactate dehydrogenase (> 2 × upper limit of normal, aOR 23.21, 95% CI 3.66–147.11, p < 0.001), thrombocytopenia (< 120,000/µl, aOR 11.66, 95% CI 2.49–54.70, p = 0.002), anemia (Hb < 10 g/dl, aOR 3.21, 95% CI 1.17–8.82, p = 0.024), and C-reactive protein (≥ 30 mg/l, aOR 3.44, 95% CI 1.13–10.45, p = 0.029) as predictors, while renal replacement therapy was not related to mortality (aOR 1.15, 95% CI 0.68–1.93, p = 0.611). Conclusion The identified predictors include routinely measured and universally available parameters. Their assessment might facilitate risk stratification in this highly vulnerable cohort as early as at initial medical evaluation for SARS-CoV-2. KW - chronic kidney disease KW - COVID-19 KW - LEOSS KW - predictive factor KW - SARS-CoV-2 Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-308957 SN - 0300-8126 SN - 1439-0973 VL - 49 IS - 4 ER - TY - JOUR A1 - Meintrup, David A1 - Borgmann, Stefan A1 - Seidl, Karlheinz A1 - Stecher, Melanie A1 - Jakob, Carolin E. M. A1 - Pilgram, Lisa A1 - Spinner, Christoph D. A1 - Rieg, Siegbert A1 - Isberner, Nora A1 - Hower, Martin A1 - Vehreschild, Maria A1 - Göpel, Siri A1 - Hanses, Frank A1 - Nowak-Machen, Martina T1 - Specific risk factors for fatal outcome in critically ill COVID-19 patients: results from a European multicenter study JF - Journal of Clinical Medicine N2 - (1) Background: The aim of our study was to identify specific risk factors for fatal outcome in critically ill COVID-19 patients. (2) Methods: Our data set consisted of 840 patients enclosed in the LEOSS registry. Using lasso regression for variable selection, a multifactorial logistic regression model was fitted to the response variable survival. Specific risk factors and their odds ratios were derived. A nomogram was developed as a graphical representation of the model. (3) Results: 14 variables were identified as independent factors contributing to the risk of death for critically ill COVID-19 patients: age (OR 1.08, CI 1.06–1.10), cardiovascular disease (OR 1.64, CI 1.06–2.55), pulmonary disease (OR 1.87, CI 1.16–3.03), baseline Statin treatment (0.54, CI 0.33–0.87), oxygen saturation (unit = 1%, OR 0.94, CI 0.92–0.96), leukocytes (unit 1000/μL, OR 1.04, CI 1.01–1.07), lymphocytes (unit 100/μL, OR 0.96, CI 0.94–0.99), platelets (unit 100,000/μL, OR 0.70, CI 0.62–0.80), procalcitonin (unit ng/mL, OR 1.11, CI 1.05–1.18), kidney failure (OR 1.68, CI 1.05–2.70), congestive heart failure (OR 2.62, CI 1.11–6.21), severe liver failure (OR 4.93, CI 1.94–12.52), and a quick SOFA score of 3 (OR 1.78, CI 1.14–2.78). The nomogram graphically displays the importance of these 14 factors for mortality. (4) Conclusions: There are risk factors that are specific to the subpopulation of critically ill COVID-19 patients. KW - COVID-19 KW - SARS-CoV-2 KW - risk factors KW - critically ill patients KW - comorbidities KW - lasso regression KW - nomogram Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-245191 SN - 2077-0383 VL - 10 IS - 17 ER - TY - JOUR A1 - Isberner, Nora A1 - Kraus, Sabrina A1 - Grigoleit, Götz Ulrich A1 - Aghai, Fatemeh A1 - Kurlbaum, Max A1 - Zimmermann, Sebastian A1 - Klinker, Hartwig A1 - Scherf-Clavel, Oliver T1 - Ruxolitinib exposure in patients with acute and chronic graft versus host disease in routine clinical practice-a prospective single-center trial JF - Cancer Chemotherapy and Pharmacology N2 - Purpose Knowledge on Ruxolitinib exposure in patients with graft versus host disease (GvHD) is scarce. The purpose of this prospective study was to analyze Ruxolitinib concentrations of GvHD patients and to investigate effects of CYP3A4 and CYP2C9 inhibitors and other covariates as well as concentration-dependent effects. Methods 262 blood samples of 29 patients with acute or chronic GvHD who were administered Ruxolitinib during clinical routine were analyzed. A population pharmacokinetic model obtained from myelofibrosis patients was adapted to our population and was used to identify relevant pharmacokinetic properties and covariates on drug exposure. Relationships between Ruxolitinib exposure and adverse events were assessed. Results Median of individual mean trough serum concentrations was 39.9 ng/mL at 10 mg twice daily (IQR 27.1 ng/mL, range 5.6-99.8 ng/mL). Applying a population pharmacokinetic model revealed that concentrations in our cohort were significantly higher compared to myelofibrosis patients receiving the same daily dose (p < 0.001). Increased Ruxolitinib exposure was caused by a significant reduction in Ruxolitinib clearance by approximately 50%. Additional comedication with at least one strong CYP3A4 or CYP2C9 inhibitor led to a further reduction by 15% (p < 0.05). No other covariate affected pharmacokinetics significantly. Mean trough concentrations of patients requiring dose reduction related to adverse events were significantly elevated (p < 0.05). Conclusion Ruxolitinib exposure is increased in GvHD patients in comparison to myelofibrosis patients due to reduced clearance and comedication with CYP3A4 or CYP2C9 inhibitors. Elevated Ruxolitinib trough concentrations might be a surrogate for toxicity. KW - toxicity KW - Ruxolitinib KW - graft versus host disease KW - therapeutic drug monitoring KW - CYP3A4 KW - CYP2C9 Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-266476 SN - 1432-0843 VL - 88 IS - 6 ER - TY - JOUR A1 - Isberner, Nora A1 - Gesierich, Anja A1 - Balakirouchenane, David A1 - Schilling, Bastian A1 - Aghai-Trommeschlaeger, Fatemeh A1 - Zimmermann, Sebastian A1 - Kurlbaum, Max A1 - Puszkiel, Alicja A1 - Blanchet, Benoit A1 - Klinker, Hartwig A1 - Scherf-Clavel, Oliver T1 - Monitoring of dabrafenib and trametinib in serum and self-sampled capillary blood in patients with BRAFV600-mutant melanoma JF - Cancers N2 - Simple Summary In melanoma patients treated with dabrafenib and trametinib, dose reductions and treatment discontinuations related to adverse events (AE) occur frequently. However, the associations between patient characteristics, AE, and exposure are unclear. Our prospective study analyzed serum (hydroxy-)dabrafenib and trametinib exposure and investigated its association with toxicity and patient characteristics. Additionally, the feasibility of at-home sampling of capillary blood was assessed, and a model to convert capillary blood concentrations to serum concentrations was developed. (Hydroxy-)dabrafenib or trametinib exposure was not associated with age, sex, body mass index, or AE. Co-medication with P-glycoprotein inducers was associated with lower trough concentrations of trametinib but not (hydroxy-)dabrafenib. The applicability of the self-sampling of capillary blood was demonstrated. Our conversion model was adequate for estimating serum exposure from micro-samples. The monitoring of dabrafenib and trametinib may be useful for dose modification and can be optimized by at-home sampling and our new conversion model. Abstract Patients treated with dabrafenib and trametinib for BRAF\(^{V600}\)-mutant melanoma often experience dose reductions and treatment discontinuations. Current knowledge about the associations between patient characteristics, adverse events (AE), and exposure is inconclusive. Our study included 27 patients (including 18 patients for micro-sampling). Dabrafenib and trametinib exposure was prospectively analyzed, and the relevant patient characteristics and AE were reported. Their association with the observed concentrations and Bayesian estimates of the pharmacokinetic (PK) parameters of (hydroxy-)dabrafenib and trametinib were investigated. Further, the feasibility of at-home sampling of capillary blood was assessed. A population pharmacokinetic (popPK) model-informed conversion model was developed to derive serum PK parameters from self-sampled capillary blood. Results showed that (hydroxy-)dabrafenib or trametinib exposure was not associated with age, sex, body mass index, or toxicity. Co-medication with P-glycoprotein inducers was associated with significantly lower trough concentrations of trametinib (p = 0.027) but not (hydroxy-)dabrafenib. Self-sampling of capillary blood was feasible for use in routine care. Our conversion model was adequate for estimating serum PK parameters from micro-samples. Findings do not support a general recommendation for monitoring dabrafenib and trametinib but suggest that monitoring can facilitate making decisions about dosage adjustments. To this end, micro-sampling and the newly developed conversion model may be useful for estimating precise PK parameters. KW - dabrafenib KW - trametinib KW - hydroxy-dabrafenib KW - melanoma KW - BRAF mutation KW - volumetric absorptive micro-sampling (VAMS) KW - at-home sampling KW - drug monitoring KW - population pharmacokinetics Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-288109 SN - 2072-6694 VL - 14 IS - 19 ER - TY - THES A1 - Isberner, Nora T1 - Auswirkungen von Staphylococcus aureus auf die Endothelpermeabilität in Ea.hy926-Zellen T1 - Influence of Staphylococcus aureus on endothelial permeability in Ea.hy926 cells N2 - Staphylococcus aureus (S. aureus) ist einer der häufigsten Erreger schwerer endovaskulärer Infektionen, die häufig mit einer Dissemination des Erregers in andere Organe und lebensbedrohlichen Komplikationen wie Endokarditis, Osteomyelitis oder Abszessen assoziiert sind. Entscheidender Schritt in der Pathogenese endovaskulärer Infektionen ist die Schädigung und Überwindung der Endothelbarriere. Für deren Integrität ist die Intaktheit von Zell-Zell-Verbindungen elementar, diese werden unter anderem durch Src-Kinasen reguliert. Es ist bekannt, dass S. aureus Fibronektin-Bindeproteine (FnBPs) maßgeblich für die Adhärenz und Invasion des Erregers in Endothelzellen sind. Die Invasion erfolgt über eine indirekte Bindung an α5β1-Integrine, invasive Eigenschaften finden sich in nahezu allen klinischen Isolaten. In verschiedenen Tiermodellen konnte außerdem ein Zusammenhang zwischen der Expression von FnBPs und der Dissemination von S. aureus in andere Organe gezeigt werden. Bislang ist jedoch nicht untersucht, welche Auswirkung die S. aureus-Infektion auf die Endothelbarriere hat und welche Mechanismen für die Translokation des Erregers verantwortlich sind. In dieser Arbeit wurde analysiert, ob die Infektion mit S. aureus- und S. carnosus-Stämmen in vitro zu einer Schädigung der endothelialen Integrität von EA.hy926-Zellen führt. Hierzu wurden Änderungen der transendothelialen Impedanz und der Endothelpermeabeabilität nach Infektion im xCELLigence- bzw. Transwell-System erfasst. Zytotoxische Effekte wurden durch Kristallviolettfärbungen, immunfluoreszenz-mikroskopische Untersuchungen der Mitochondrien und Nuklei sowie die Erfassung der hypodiploiden Zellkerne mittels Durchflusszytometrie quantifiziert. Zur Entschlüsselung des molekularen Mechanismus wurden Veränderungen der Adherens und Tight Junction-Proteine ZO-1 und VE-Cadherin in der Immunfluoreszenz untersucht. Die Rolle von Src-Kinasen wurde durch pharmakologische Inhibition analysiert. Es konnte gezeigt werden, dass FnBP-exprimierende S. aureus-Stämme eine Abnahme der transendothelialen Impedanz verursachen und dass es 4 und 24 Stunden nach Infektion zu einer signifikanten Zunahme der Endothelpermeabilität kommt. Zytotoxische Effekte auf die Endothelzellen durch die Infektion traten nach 24 Stunden auf, jedoch nicht nach 4 Stunden. VE-Cadherin und ZO-1 zeigten 4 Stunden nach Infektion eine FnBP-abhängige Konformationsänderung und Reduktion der Signalintensität. Außerdem konnte demonstriert werden, dass die Inhibition von Src-Kinasen den Anstieg der Endothelpermeabilität signifikant reduziert. In dieser Arbeit wurde zum ersten Mal belegt, dass S. aureus FnBPs eine Erhöhung der Endothelpermeabilität bewirken. Während hierfür zu späten Zeitpunkten Apoptose verantwortlich ist, muss nach 4 Stunden ein anderer Mechanismus ursächlich sein. Da es zu einer Abschwächung der ZO-1- und VE-Cadherin-Signalintensität in der Immunfluoreszenz kam, ist anzunehmen, dass Adherens und Tight Junctions durch die Infektion geschädigt werden. Es ist bekannt, dass Src-Kinasen durch die Infektion mit S. aureus aktiviert werden. Außerdem sind sie elementar für die Regulation der Endothelpermeabilität und vermitteln diesen Effekt unter anderem über eine Phosphorylierung von Adherens und Tight Junction-Proteinen. Eine Src-vermittelte Phosphorylierung von Zell-Zell-Verbindungsproteinen wäre daher eine mögliche Erklärung für die beobachteten Veränderungen von ZO-1 und VE-Cadherin. Dieser Mechanismus könnte Wegbereiter für die parazelluläre Passage über die Endothelbarriere sein. Darüber hinaus könnte die erhöhte Endothelpermeabilität den Zugang zur Extrazellulärematrix und zum größten Pool an Fibronektin und Integrinen ermöglichen und so die Invasion und Transzytose begünstigen. Die hier gewonnenen Ergebnisse tragen dazu bei, die komplexe Interaktion zwischen S. aureus und dem Endothel und somit wichtige Schritte in der Pathogenese endovaskulärer Infektionen besser zu verstehen und neue Zielstrukturen für therapeutische Interventionen zu identifizieren. N2 - Staphylococcus aureus (S. aureus) is a major cause of severe endovascular infections which are frequently associated with bacterial dissemination to other organs and life-threatening complications such as infective endocarditis, osteomyelitis or abscess formation. Damage to the endothelial barrier and bacterial extravasation are of vital importance in development of endovascular infections. Intercellular junctions are crucial for the integrity of the endothelial barrier; they are partially regulated by Src Family Protein-tyrosine Kinases. It has been well characterized that S. aureus fibronectin-binding proteins (FnBP) are decisive for adherence to and invasion of endothelial cells. Invasion is mediated by indirect bridging of fibronectin to α5β1-integrins via FnBPs. Invasive characteristics can be found in nearly all clinical isolates. Moreover, the link between expression of FnBPs and S. aureus dissemination into surrounding tissues has been demonstrated repeatedly in animal models. Despite the importance of S. aureus in endovascular diseases, the effect of S. aureus infection on endothelial barrier function and putative mechanisms for translocation have not yet been studied. The aim of this thesis was to evaluate whether infection with different S. aureus and S. carnosus strains leads to impairment of endothelial integrity in EA.hy926 cells. Changes in transendothelial impedance and endothelial permeability upon infection were measured using the xCELLigence- or transwell-system respectively. Cytotoxic effects were quantified by crystal violet staining, immunofluorescence staining of nuclei and mitochondria as well as by detection of hypodiploid nuclei using flow cytometry. Immunofluorescence staining of ZO-1 and VE—Cadherin was performed to investigate morphological alterations in intercellular junctions. The role of Src Family Protein-tyrosine Kinases was analyzed by pharmacological inhibition. In this study it was demonstrated that S. aureus strains expressing FnBPs lead to a decrease in transendothelial impedance and cause a significant increase in endothelial permeability 4 and 24 hours after infection. Whereas cytotoxic effects were observed after 24 hours, cells were completely viable 4 hours after infection. After 4 hours FnBP-dependent conformational changes of VE-cadherin and ZO-1 as well as a loss of signal intensity were detected. Furthermore, the FnBP-mediated increase in endothelial permeability was significantly reduced by using Src Family Protein-tyrosine Kinases-inhibitors. In this study it was shown for the first time that S. aureus FnBPs cause an increase in endothelial permeability. While apoptosis is the underlying mechanism 24 hours after infection, other mechanisms could be identified for the time point 4 hours. Since a loss of signal intensity of ZO-1 and VE-Cadherin was detected, it can be assumed that adherence and tight junctions are impaired upon infection. It has been well characterized that Src Family Protein-tyrosine Kinases are activated upon S. aureus infection and that they are decisive in regulation of endothelial permeability. This effect is mediated by phosphorylation of adherence and tight junction proteins. Hence a Src Family Protein-tyrosine Kinase-mediated phosphorylation of intercellular junction proteins is a conceivable mechanism for the observed change in ZO-1 and VE-cadherin, thus possibly enabling paracellular traverse of the endothelial barrier. On the other hand the increase of endothelial permeability could facilitate access to the extracellular matrix and thus to the biggest pool of fibronectin and integrins, hence promoting bacterial invasion and transcytosis. The obtained results help to understand the complex interaction between S. aureus and endothelial barrier, thus facilitating the understanding of the pathogenesis of endovascular S. aureus infections and possibly identifying new therapy targets. KW - Staphylococcus aureus KW - Staphylococcus aureus KW - Endothelpermeabilität KW - Fibronektin-Bindeprotein Y1 - 2015 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-137303 ER - TY - JOUR A1 - Gerner, Bettina A1 - Aghai-Trommeschlaeger, Fatemeh A1 - Kraus, Sabrina A1 - Grigoleit, Götz Ulrich A1 - Zimmermann, Sebastian A1 - Kurlbaum, Max A1 - Klinker, Hartwig A1 - Isberner, Nora A1 - Scherf-Clavel, Oliver T1 - A physiologically-based pharmacokinetic model of ruxolitinib and posaconazole to predict CYP3A4-mediated drug–drug interaction frequently observed in graft versus host disease patients JF - Pharmaceutics N2 - Ruxolitinib (RUX) is approved for the treatment of steroid-refractory acute and chronic graft versus host disease (GvHD). It is predominantly metabolized via cytochrome P450 (CYP) 3A4. As patients with GvHD have an increased risk of invasive fungal infections, RUX is frequently combined with posaconazole (POS), a strong CYP3A4 inhibitor. Knowledge of RUX exposure under concomitant POS treatment is scarce and recommendations on dose modifications are inconsistent. A physiologically based pharmacokinetic (PBPK) model was developed to investigate the drug–drug interaction (DDI) between POS and RUX. The predicted RUX exposure was compared to observed concentrations in patients with GvHD in the clinical routine. PBPK models for RUX and POS were independently set up using PK-Sim\(^®\) Version 11. Plasma concentration-time profiles were described successfully and all predicted area under the curve (AUC) values were within 2-fold of the observed values. The increase in RUX exposure was predicted with a DDI ratio of 1.21 (C\(_{max}\)) and 1.59 (AUC). Standard dosing in patients with GvHD led to higher RUX exposure than expected, suggesting further dose reduction if combined with POS. The developed model can serve as a starting point for further simulations of the implemented DDI and can be extended to further perpetrators of CYP-mediated PK-DDIs or disease-specific physiological changes. KW - physiologically based pharmacokinetic (PBPK) modeling KW - ruxolitinib KW - posaconazole KW - drug–drug interactions (DDIs) KW - graft versus host disease KW - cytochrome P450 3A4 (CYP3A4) KW - pharmacokinetics Y1 - 2022 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-297261 SN - 1999-4923 VL - 14 IS - 12 ER - TY - JOUR A1 - Aghai, Fatemeh A1 - Zimmermann, Sebastian A1 - Kurlbaum, Max A1 - Jung, Pius A1 - Pelzer, Theo A1 - Klinker, Hartwig A1 - Isberner, Nora A1 - Scherf-Clavel, Oliver T1 - Development and validation of a sensitive liquid chromatography tandem mass spectrometry assay for the simultaneous determination of ten kinase inhibitors in human serum and plasma JF - Analytical and Bioanalytical Chemistry N2 - A liquid chromatography tandem mass spectrometry method for the analysis of ten kinase inhibitors (afatinib, axitinib, bosutinib,cabozantinib, dabrafenib, lenvatinib, nilotinib, osimertinib, ruxolitinib, and trametinib) in human serum and plasma for theapplication in daily clinical routine has been developed and validated according to the US Food and Drug Administration andEuropean Medicines Agency validation guidelines for bioanalytical methods. After protein precipitation of plasma samples withacetonitrile, chromatographic separation was performed at ambient temperature using a Waters XBridge® Phenyl 3.5μm(2.1×50 mm) column. The mobile phases consisted of water-methanol (9:1, v/v) with 10 mM ammonium bicarbonate as phase A andmethanol-water (9:1, v/v) with 10 mM ammonium bicarbonate as phase B. Gradient elution was applied at a flow rate of 400μL/min. Analytes were detected and quantified using multiple reaction monitoring in electrospray ionization positive mode. Stableisotopically labeled compounds of each kinase inhibitor were used as internal standards. The acquisition time was 7.0 min perrun. All analytes and internal standards eluted within 3.0 min. The calibration curves were linear over the range of 2–500 ng/mLfor afatinib, axitinib, bosutinib, lenvatinib, ruxolitinib, and trametinib, and 6–1500 ng/mL for cabozantinib, dabrafenib, nilotinib,and osimertinib (coefficients of correlation≥0.99). Validation assays for accuracy and precision, matrix effect, recovery,carryover, and stability were appropriate according to regulatory agencies. The rapid and sensitive assay ensures high throughputand was successfully applied to monitor concentrations of kinase inhibitors in patients. KW - kinase inhibitors KW - therapeutic drug monitoring KW - liquid chromatography tandem mass spectrometry (LC-MS/MS KW - afatinib KW - osimertinib Y1 - 2021 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-231925 SN - 1618-2642 VL - 413 ER -